Search Results
Your search for ,foR matches 32668 pages
Showing 19951 - 20000Social Media: A Knowledge-Sharing Tool in Oncology
Social media is a uniquely positioned platform that can spread specific knowledge to a larger audience. Unlike traditional media, it allows anyone to join the conversation, and according to the Pew Research Center, it is here to stay, with 79% of online American adults using Facebook and 24% using...
QOPI® Certification Program Certifies First Practice in Brazil
On April 5, ASCO announced that Instituto de Oncologia do Vale (IOV) was the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). IOV is the second international practice to achieve this milestone in...
Support the Conquer Cancer Foundation at the 2017 ASCO Annual Meeting
Lace Up to Conquer Cancer The ASCO Annual Meeting involves a lot of walking—wear comfortable shoes and show your support for cancer research by participating in the Conquer Cancer Foundation (CCF) Laces campaign. Make a donation to CCF when you register for the 2017 Annual Meeting, and you will...
ELCC 2017: Development and Validation of Lung Toxicity Prediction Models Aids Effective Use of Radiotherapy in NSCLC
Validation using patient data of an outcome prediction model for the development of dyspnea subsequent to radiotherapy revealed that the prognostic factors in the model did not adequately predict for delta toxicity endpoints, according to results reported by Defraene et al at the 2017 European Lung ...
Donor Spotlight: Conquering Cancer With Kelly Cares Foundation
Kelly Cares Foundation recently became one of the newest supporters of the Conquer Cancer Foundation of ASCO Young Investigator Awards, the flagship program begun in 1984 to support early-career cancer researchers. The mission of Kelly Cares Foundation is to inspire hope by investing resources to...
Cancer Research UK Awards Six U.S. Scientists $87 Million as Part of ‘Grand Challenge’
Cancer Research UK has announced that six leading American scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research. The initial $87 million “Grand Challenge” fund will be distributed across 4 international teams of academics from 6...
Neoadjuvant Immunotherapy in High-Risk Melanoma: A New Approach
Melanoma is an immunogenic tumor, as it expresses various melanoma-specific antigens. However, it is both biologically and clinically heterogeneous. Biologically, it expresses different melanoma antigens and has diverse genetic profiles among different patients. Clinically, it varies in the amount ...
Prognostic and Predictive Effects of TP53 With KRAS or EGFR Mutation Status in NSCLC
In a pooled analysis of four trials of platinum adjuvant therapy vs observation in resected early-stage non–small cell lung cancer (NSCLC), Shepherd et al found no prognostic effect of KRAS or EGFR with TP53 comutation but a potential negative predictive effect for adjuvant therapy with TP53...
Final, 10-Year Follow-up of Phase III Trial on Adding Gemcitabine to Adjuvant Therapy in Breast Cancer
The final, 10-year follow-up of the ‘all comers’ tAnGo trial, reported by Earl et al in The Lancet Oncology, continued to show no overall benefit of adding gemcitabine to adjuvant therapy in women with early-stage breast cancer. The trial, initiated in 2001, included patients...
SWOG Launches First Prospective Registration Trial With Atezolizumab in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
The standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer is radical cystectomy. Novel therapies that allow patients to preserve their bladder are urgently needed. SWOG (formerly the Southwest Oncology Group), a member of...
Karmanos Cancer Institute Now Offers Image-Fusion Technology to Detect Prostate Cancer
The Barbara Ann Karmanos Cancer Institute is using a sophisticated new way to diagnose and treat prostate cancer more effectively. Urology specialists at Karmanos have begun using the UroNav Fusion Biopsy System, which fuses three-dimensional MRI (magnetic resonance imaging) images of the prostate...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in various types of high-grade, aggressive non-Hodgkin lymphomas (NHLs), including peripheral T-cell lymphomas, central...
Expert Point of View: Kelly M. McMasters, MD, PhD
“More and more, we are finding that traditional anatomic TNM staging has significant limitations in predicting prognosis, especially in such cases where response to therapy is an important consideration,” commented session moderator Kelly M. McMasters, MD, PhD, a surgical oncologist at the...
Neo-Bioscore Improves Staging of Breast Cancer Treated With Neoadjuvant Chemotherapy
A new score that incorporates tumor biology and response outperforms conventional histopathologic criteria for the staging of breast cancer treated with neoadjuvant chemotherapy, finds a retrospective validation cohort study.1 Investigators led by John R. Bergquist, MD, MS, MA, a general surgery...
Hyperthermic Intraperitoneal Chemoperfusion May Be Efficacious for Peritoneal Metastases
Hyperthermic intraperitoneal chemoperfusion is efficacious when used as part of multimodality therapy for low-volume peritoneal metastases of gastric cancer, suggests a prospective single-arm phase II trial.1 Among the 19 patients enrolled, all of whom had stage IV disease with either...
Expert Point of View: Ashish Saxena, MD, PhD
After the data were presented, Ashish Saxena, MD, PhD, Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the NewYork-Presbyterian Hospital, New York, weighed in on the CA209-003 study. “The results of this trial are exciting and give hope to...
Five-Year Survival Quadrupled in Responders to Immunotherapy for Non–Small Cell Lung Cancer
At 5 years, the overall survival rate was 16% in patients with advanced non–small cell lung cancer (NSCLC) treated with single-agent nivolumab (Opdivo), according to follow-up of a phase Ib dose-ranging study (CA209-003), presented at the American Association for Cancer Research (AACR) Annual...
Expert Point of View: Gary K. Schwartz, MD
Gary K. Schwartz, MD, Chief of Hematology/Oncology and Deputy Director of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center, New York, is not sold on using the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for all patients with...
Nivolumab/Ipilimumab Combination Improves Survival Over Ipilimumab Alone in Patients With Melanoma
The race is on to identify combinations of immune checkpoint inhibitors that can improve outcomes over the use of immune checkpoint inhibitor monotherapy. Updated results of the phase III CheckMate 067 trial found the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved survival in...
On the Variance of Cancer Outcomes by Time and Geography
A recent study by Mokdad and colleagues, reviewed in this issue of The ASCO Post, looks at cancer demographic data for 28 cancers and compares mortality rates in 1980 to results in 2014.1 Publishing mortality rates by geographic area and the observation of significant differences is not new. The...
ELCC 2017: Study Shows White Blood Cell–Boosting Drugs Safe During Small Cell Lung Cancer Chemoradiotherapy
A late-breaking subanalysis of the phase III CONVERT trial presented by Gomes et al at the 2017 European Lung Cancer Conference (ELCC) shows that white blood cell–boosting drugs are safe during concurrent chemoradiotherapy of small cell lung cancer (SCLC, Abstract LBA2_PR). “The...
ELCC 2017: Some Patients With Lung Cancer Benefit From Immunotherapy Even After Disease Progression
Some patients with advanced lung cancer benefit from immunotherapy, even after the disease has progressed as evaluated by standard criteria, according to research presented by Artal-Cortes et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 96PD). The findings pave the way for certain ...
ELCC 2017: White Blood Cell Count May Predict Response to Lung Cancer Immunotherapy
White blood cell counts may predict whether patients with lung cancer will benefit from immunotherapy, according to research presented by Tiseo et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 30PD). “Immune checkpoint inhibitors such as nivolumab [Opdivo] and...
ELCC 2017: Osimertinib Improves Symptoms in Advanced Lung Cancer
Osimertinib (Tagrisso) improved cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented by Lee et al at the 2017 European Lung Cancer Conference (ELCC, Abstract 85O). “With my...
Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Chen et al, the phase II KEYNOTE-087 trial has shown that the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) is highly active in patients with relapsed or refractory classical Hodgkin lymphoma. Findings in the study ...
IMPAKT 2017: Few Variations in Somatic Mutations Observed Between Pregnant and Nonpregnant Patients With Breast Cancer
Findings comparing the mutational landscape in pregnant and nonpregnant patients with breast cancer that sought to define whether the disease may have a different biology in pregnant women were reported by Loibl et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract...
IMPAKT 2017: Luminal Androgen Receptor Subtype of Triple-Negative Breast Cancer Demonstrates Sensitivity to CDK4/6 Inhibition
Researchers have identified a subtype of triple-negative breast cancer that may be responsive to inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), according to findings presented by Asghar et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract 44P). This study also...
IMPAKT 2017: High Baseline Tumor-Infiltrating Lymphocyte Levels Signal Superior Responses in HER2-Positive Breast Cancer
Baseline levels of tumor-infiltrating lymphocytes (TILs) in pretreatment biopsies from patients with HER2-positive breast cancer are significantly associated with pathologic complete response rates following neoadjuvant chemotherapy plus anti-HER2 agents (trastuzumab [Herceptin], lapatinib...
WHO to Begin Pilot Prequalification of Biosimilars for Cancer Treatment
This year, the World Health Organization (WHO) will launch a pilot project for prequalifying biosimilar medicines, a step toward making some of the most expensive treatments for cancer more widely available in low- and middle-income countries. The decision comes after a 2-day meeting in Geneva...
ASCO Provisional Clinical Opinion: Second-Line Hormonal Therapy for Chemotherapy-Naive Castration-Resistant Prostate Cancer
As reported by Katherine S. Virgo, PhD, MBA, of Emory University, and colleagues in the Journal of Clinical Oncology, ASCO has issued a provisional clinical opinion on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer. The provisional clinical opinion applies...
Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology by Kurian et al, surveys in a population-based sample of patients recently diagnosed with breast cancer indicate that many undergo genetic risk testing without seeing a genetics counselor and that many with BRCA1/2 variants of uncertain significance...
AMA Statement on House Passage of American Health Care Act
American Medical Association (AMA) President Andrew W. Gurman, MD, released the following statement today after the U.S. House of Representatives passed the American Health Care Act: “The bill passed by the House today will result in millions of Americans losing access to quality,...
AANS 2017: Genetic Underpinnings of Desmoplastic Infantile Ganglioglioma/Astrocytoma
Winner of the American Brain Tumor Association Young Investigator Award Anthony C. Wang, MD, a neurosurgeon at the University of California Los Angeles (UCLA) Mattel Children’s Hospital and the David Geffen School of Medicine at UCLA, presented his research findings on desmoplastic infantile...
New Spanish-Language Videos and Brochures From ASTRO Provide an Overview of Radiation Therapy
Spanish-speaking patients with cancer have new tools to help them understand treatment options for their disease. The American Society for Radiation Oncology (ASTRO) has released a series of Spanish-language patient videos on radiation therapy for cancer, including breast, prostate, lung, brain,...
PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma
According to a study by Skinner et al, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squamous cell carcinoma is sensitive to radiation, HPV-negative tumors are...
Tumor CD274 (PD-L1) Expression and Survival With Aspirin Use in Colorectal Cancer
According to a study reported by Hamada et al in the Journal of Clinical Oncology, postdiagnosis aspirin use was associated with improved survival vs nonuse among patients with colorectal cancer who have lower, but not higher, tumor levels of CD274 (programmed cell death 1 ligand 1; PD-L1). Study...
Adding Bevacizumab to Paclitaxel-Carboplatin in Recurrent Platinum-Sensitive Ovarian Cancer
In a phase III trial (NRG Oncology/Gynecologic Oncology Group GOG-0213 trial) reported in The Lancet Oncology, Coleman et al found evidence of an overall survival advantage with the addition of bevacizumab (Avastin) to paclitaxel-carboplatin in recurrent platinum-sensitive ovarian cancer. The...
Cancer Mortality Trends in the United States Vary Widely by County From 1980 to 2014
In a study reported in JAMA, Ali H. Mokdad, PhD, and colleagues from the University of Washington, Seattle, found that cancer mortality rates in the United States dropped from 240.2 to 192.0 per 100,000 population between 1980 and 2014.1 Mortality rates varied widely among U.S. counties for...
One Physician’s Experience
In a separate interview, George Ansstas, MD, a medical neuro-oncologist at Siteman Cancer Center, Washington University, St. Louis, discussed his experience in treating patients with tumor-treating fields. He has treated about 35 patients with glioblastoma in the first-line setting and 20 with...
Expert Point of View: George Demetri, MD
“I am intrigued by this study. I have no idea by which molecular mechanism this [tumor-treating fields therapy] works, but the data are the data,” said George Demetri, MD, of Dana-Farber Cancer Center, Boston. Dr. Demetri moderated the press conference where these data were discussed. “A panoply...
‘Out-of-the-Box’ Approach Plus Temozolomide Extends Survival in Glioblastoma
Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with...
Selected Clinical Trials of CDK4/6 Inhibitors
This Clinical Trials Resource Guide includes a selection of actively recruiting clinical trials of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib in multiple tumor types. All of the studies here and many others are listed on the National...
First-in-Human Experience With Abemaciclib
The investigational cyclin D–dependent kinase (CDK) 4/6 inhibitor abemaciclib was recently evaluated in several solid tumor types in a phase I multicenter trial.1 Given primarily as a single agent and with continuous dosing, abemaciclib showed encouraging early signals of clinical activity not only ...
CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future
Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...
CDK4/6 Inhibitors: Their Role in Breast Cancer
The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...
Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting
The novel mechanism of action of drugs that inhibit the cyclin D–dependent kinases CDK4 and CDK6 has prompted effective new treatment strategies. Although the bulk of the data supporting the use of selective CDK4/6 inhibitors is currently in breast cancer, patients with other tumor types are...
Continuing Education Information
This CE/CME/CEU-accredited supplement is jointly provided by To earn credit/contact hours, you must read all the articles in this supplement and then go to: https://education.annenberg.net/cdk46inhibition Release date: May 10, 2017 Expiration date: May 10, 2018Annenberg Center for Health...
Genomic Intratumor Heterogeneity and Evolution of NSCLC Tumors
In a study reported in The New England Journal of Medicine, Jamal-Hanjani et al found that early stage non–small cell lung cancer (NSCLC) tumors were characterized by widespread intratumor genomic heterogeneity and that increased subclonal copy-number alterations in this context were...
Long-Term Follow-up of German Hodgkin Study Group Trials in Early-Stage Hodgkin Lymphoma
In an article in the Journal of Clinical Oncology, Sasse et al reported long-term follow-up of German Hodgkin Study Group trials in early-stage favorable and unfavorable Hodgkin lymphoma. The updates cover the HD7 and HD10 trials in favorable disease and the HD8 and HD11 trials in unfavorable...
ELCC 2017: Men May Need More Frequent Lung Cancer Screening Than Women
Men may need more frequent lung cancer screening than women, according to research to be presented by Koo et al at the 2017 European Lung Cancer Conference (ELCC). The U.S. Preventive Services Task Force recommends annual screening for lung cancer with low-dose computed tomography (CT) in adults...
